



Molecular Docking of Isolated Alkaloids for Possible α -Glucosidase Inhibition

Noor Rahman ¹^(D), Ijaz Muhammad ²^(D), Gul-E-Nayab ², Haroon Khan ^{3,*}^(D), Michael Aschner ⁴^(D), Rosanna Filosa ^{5,6} and Maria Daglia ^{7,8,*}^(D)

- ¹ Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan-23200, KP, Pakistan; noorbiochemist@gmail.com
- ² Department of Zoology, Abdul Wali Khan University Mardan, Mardan-23200, KP, Pakistan; ijazmawkum@gmail.com (I.M.); nayabawkum@gmail.com (G.-E.-N.)
- ³ Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan-23200, KP, Pakistan
- ⁴ Department of Molecular Pharmacology, Albert Einstein College of Medicine Forchheimer 209 1300 Morris Park Avenue Bronx, NY 10461, USA; michael.aschner@einstein.yu.edu
- ⁵ Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", via L. De Crecchio 7, 80138 Naples, Italy; Rosanna.FILOSA@unicampania.it
- ⁶ Consorzio Sannio Tech-AMP Biotec, Appia Str. 7, 82030 Apollosa, BN, Italy
- ⁷ Department of Pharmacy, University of Naples Federico II, 80138 Naples, Italy
- ⁸ International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China
- * Correspondence: hkdr2006@gmail.com or haroonkhan@awkum.edu.pk (H.K.); maria.daglia@unipv.it (M.D.)

Received: 31 August 2019; Accepted: 16 September 2019; Published: 27 September 2019



Abstract: Diabetes mellitus, one of the most common endocrine-metabolic disorders, has caused significant morbidity and mortality worldwide. To avoid sugar digestion and postprandial hyperglycemia, it is necessary to inhibit α -glucosidase, a digestive enzyme with an important role in carbohydrate digestion. The criteria for the selection of alkaloids are based on their in vitro and in vivo activities on glucose modulation. The current study assessed the bonding potential of isolated alkaloids with the targeted protein. For this purpose, the 3D structure of the target protein (α -glucosidase) was reproduced using MODELLER 9.20. The modeled 3D structure was then validated and confirmed by using the RAMPAGE, ERRAT, and Verify3D online servers. The molecular docking of 32 alkaloids reported as α -glucosidase inhibitors, along with reference compounds (acarbose and miglitol), was done through MOE-Dock applied in MOE software to predict the binding modes of these drug-like compounds. The results revealed that nummularine-R and vindoline possess striking interactions with active site residues of the target protein, and were analogous to reference ligands. In conclusion, the current study provided a computational background to the α -glucosidase inhibitors tested. This novel information should facilitate the development of new and effective therapeutic compounds for the treatment of diabetes mellitus.

Keywords: α-glucosidase; plant alkaloids; molecular docking; new drug discovery

1. Introduction

The digestive enzyme, α -glucosidase, has an important role in carbohydrate digestion and is responsible for the biosynthesis of glycoproteins. Several α -glucosidases can not only perform the hydrolysis of oligosaccharides and artificial α -glycosides with α -glycosidic bonds, but can also hydrolyze α -glucans such as glycogen and water-soluble starch [1–3]. α -glucosidase is the primary enzyme for digestion of carbohydrates in the small intestine. α -glucosidase is different from β -glucosidase because it acts on the 1,4- α bond [4–7]. For cellular growth and development in plants, glucose produced by the activity of these enzymes is used as a major energy source [8]. These enzymes



are also inherent to various plant tissues, such as seeds, leaves, fruit, and roots. In the absence of α -amylase, α -glucosidase starts the breakdown of natural starch granules in different parts of plants such as barley seeds and pea chloroplasts [8–10]. The therapeutic potential of alkaloids has long been recognized for the treatment of various human disorders [11–14].

Alongi et al., 2018 [2] showed that conophylline **1** isolated from the leaves of *Ervatamia microphylla* exhibits significant antidiabetic effects in streptozotocin-induced diabetic rats [15]. Compounds **2–5** were isolated from the leaves of *Murraya koenigii* [3,4]. Compounds **6–8** were isolated from the stems of *Tinospora cordifolia* [16,17]. Compounds **9–11** were reported by Flanagan et al., 1978 [5] from the leaves of *Catharanthus roseus*. Compounds **12–14** were isolated from whole plant extracts of *Ziziphus oxyphylla* [18,19]. Compounds **15–21** were isolated from the roots and rhizomes of *Berberis lyceum*, *Coptidis rhizome*, and *Coptis japonica* [20–22] and compound **22** was isolated from the roots of *Berberis brevissima* and *Berberis parkeriana* [23]. Compounds **27–31** were reported by Arinaminpathy et al. [6] to be from the leaves of *Tecoma stans*. Compounds **27–31** were reported from seed extracts of *Nigella glandulifera* [7]. *Brassica oleracea* var. *capitata* seeds contain compound **32** [15–21,23–26].

An advantage of in silico approaches in structure-based drug design is that they minimize the time as well as the cost of developing ideas for new targets and potential lead compounds [8].

The aim of this research article was to assess the interaction of these reported antidiabetic alkaloids with target proteins such as α -glucosidase and to find novel information on active sites of α -glucosidase for the development of effective inhibitors.

2. Methodology

2.1. Target Sequence Retrieval

The protein sequence of human α -glucosidase with accession no. ABI53718.1 was downloaded from the NCBI (National Centre for Biotechnology Information) database in a FASTA format (a text-based format for representing nucleotide or peptide sequences with single-letter codes). The FASTA sequence of the protein was used for subsequent analysis to build the homology model.

2.2. Template Selection and Alignment

The query sequence was then used in the BLASTp program by the NCBI by selecting the Protein Data Bank (PDB) to identify homologs in the PDB (RCSB Protein Databank). We selected three templates with the PDB IDs 5KZW, 5NN4, and 5NN3 with 99% identity (https://www.rcsb.org) [9,10] for alignment and sequence identity of target protein structure prediction. Chimera 1.13 (developed by the resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, CA, USA with support from NIH P41-GM103311) was used for target–template alignment and superposition.

2.3. Homology Modeling

The protein sequence was subjected to homology modeling using MODELLER 9.20 (maintained by Ben Webb at the department of Biopharmaceutical Sciences and Pharmaceutical Chemistry, and California Institute for Quantitative Biomedical Research, Mission, CA, USA). Through sequence alignment against those of previously known crystal structures, the template structure was predicted. Modeled structures per protein are generated by the MODELLER and one structure was chosen on the basis of root mean square deviation (RMSD) between the template and generated models.

2.4. Validation of the Modeled Structure

The obtained modeled structure of the query protein was verified for its stereo-chemical quality by using RAMPAGE (http://mordred.bioc.cam.ac.uk/~{}rapper/rampage.php), Verify3D (http://servicesn.mbi.ucla.edu/Verify3D/), and ERRAT (https://servicesn.mbi.ucla.edu/ERRAT/) servers to check the quality of the predicted structure.

2.5. Active Site Prediction

The active site was predicted by using the site finder option of using MOE (Molecular Operating Environment) software. The site finder option was used to calculate possible active sites in α -glucosidase from the 3D atomic coordinates of the receptor. Calculations were made to determine potential sites for ligand binding and docking, and restriction sets for rendering partial molecular surfaces [27].

2.6. Alkaloids Selection

Alkaloids are one of the most studied and widely distributed classes of secondary metabolites. The selection criteria for these alkaloids is based on their in vitro and in vivo activities on glucose inhibition. Plant alkaloids constitute 16.5% of reported natural products, and comprise almost 50% of plant-derived natural products of pharmaceutical and biological significance. About 35.9% of the reported alkaloids have been tested biologically in 20 or more assays as being pharmaceutically significant [11].

2.7. Preparation of Ligand for Docking Analysis

All the ligands or molecules involved in our study were collected from the available literature. All these molecular structures were reproduced in Chem-Draw ultra-version 12.0.2.1076 (2010) and then all ligands were saved in mol format with the aim to open these files in MOE after structure preparation, and these were protonate 3D at a temperature of 300 °C and pH 7 and energy minimized through MOE, using default parameters. The MMFF94× force field was used with no periodicity and the constraints were maintained at the rigid water molecule level.

2.8. Preparation of Protein and Molecular Docking

The modeled structure of α -glucosidase was 3D protonated and then energy minimization was performed using the MOE software with default parameters as mentioned above. For molecular docking, receptors were subjected and polar hydrogens were added. While performing docking, the ligand atom was selected and rescoring1 was set at London dG and rescoring2 at GBVI/WSA dG, running so as to note the ligand interaction with protein. Protein-ligand docking score, ligand properties, and 2D and 3D structures were saved.

3. Results

3.1. Target-Template Alignment

The target sequence of α -glucosidase that was aligned with 5KZW by the Chimera software showed 99% similarities. During alignment the target protein (α -glucosidase) was superimposed on the template sequence (5KZW) shown in Figure 1. Results of target protein and template sequence alignment are in Figure 2.



Figure 1. Superposition of target (red) and template (green).

		1	11	21	31	41
Alpha Glucosidase.pdb, chain A	79	PTOCOVPPNS	REDCAPOKAL	TOEOCEARGO	CYIPAKOBLO	GAQ.
DREW, Chain A	10	51	61	71	81	91
RMSD: ca Aloha Glucosidase odb. chain A	123	COPWCEEPPS	YPSYKLENIS	SSENGYTATL	TRTTPTFFPK	DILTIBIDYM
Skzw, chain A	123	GOPWEFFPPS	YPSYKLENLS	SSEMGYTATL	TRTTPTFFPK	DILTERLOVM
RMSD: ca		101	111	121	131	141
Alpha Glucosidase.pdb, chain A Skew, chain A	173	METENRLHFT	I KOPANRRYE I KOPANRRYE	VPLETPRVHS VPLETP	RAP	SPLYSVEFSE
01/20		151	161	171	181	191
Alpha Glucosidase.pdb, chain A	216	EPFGVIVHRQ	LOGRVLLNTT	VAPLEFADQE	LOLSTSLPSO	YITGLAEHLS
okzw, chain A	216	EPFGVIVHRQ	LUGRVLLNTT	VAPLEFADQE 301	1QLSTSLPSQ	YITGLAEHLS
RMSD: ca		201		441	231	241
Alpha Glucosidase.pdb, chain A Skzw, chain A	266	PLMLSTSWTR	ITLWNRDLAP	TPGANLYGSH TPGANLYGSH	PFYLALEDGG	SAHGVFLLNS
D1100		251	261	271	281	291
Alpha Glucosidase.pdb, chain A	316	NAMOVVLOPS	PALSWRSTGG	ILDVYIFLGP	EPKSVVQQYL	DVVGYPFMPP
Skzw, chain A	316	NAMOVVLOPS	PALSWRSTGG	ILDVYIFLGP	EPKSVVQQYL	DVVGYPFMPP
RMSD: ca		301	311	941	231	241
Alpha Glucosidase.pdb, chain A Skzw, chain A	366	YWGLGFHLCR	WGYSSTAITR WGYSSTAITR	QVVENMTRAH QVVENMTRAH	FPLOVGWNDL	DYMDSRRDFT
Daven as		351	361	371	381	391
Alpha Glucosidase.pdb, chain A	416	FNKDGFROFP	AMVQELHQGG	RRYMMIVDPA	ISSSGPAGSY	RLYDEGLARG
SK2W, Chain A	416	FNKOGFROFP	AMVGELHOGG	RRYMMIVOPA 421	ISSSGPAGSY	RPYDEGLRRG
RMSD: ca			411	441	431	
Alpha Glucosidase.pdb, chain A Skzw, chain A	466	VEITNETGOP	LIGKVWPGST	AFPOFTNPTA	LAWWEDMVAE	FHOOVPFOOM
		A	and the second second second second second second	and a standard and and a standard a standard and a standard and a standard a standard a standard a standard a s		
RMSD ca		451	461	471	481	491
RMSD: ca Alpha Glucosidase.pdb, chain A Skrw. chain A	516	451 WIDMNEPSNE	461	471 NELENPPYVP	481 GVVGGTLQAA	491 TICASSHOFL
RMSD.ca Alpha Glucosidase.pdb, chain A Skzw, chain A	516 516	451 WIDMNEPSNF WIDMNEPSNF 501	461 IRGSEDGCPN IRGSEDGCPN 511	471 NELENPPYVP NELENPPYVP 521	481 GVVGGTLQAA GVVGGTLQAA 531	491 TICASSHQFL TICASSHQFL 541
RMSD: ca Alpha Glucosidase.pdb, chain A Skzw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A	516 516	451 WIDMNEPSNF Sol	461 IRGSEDCCPN IRGSEDCCPN 511 GLTEAIASHR	471 NELENPPYVP NELENPPYVP 521	481 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG	491 TICASSHQFL TICASSHQFL 541 HORYAGHWTQ
RMSD ca Alpha Glacosidase.pdb, chain A Skzw, chain A RMSD ca Alpha Glacosidase.pdb, chain A Skzw, chain A	516 516 566	451 WIDMNEPSNF 501 STHYNLHNLY STHYNLHNLY	461 IRGSEDOCPN IRGSEDOCPN 511 GLTEAIASHR GLTEAIASHR	471 NELENPPYVP S21 ALVKARGTRP	481 GVVGGTLQAA S31 FVISRSTFAG FVISRSTFAG	491 TICASSHOFL TICASSHOFL 541 HGRYAGHWYG HGRYAGHWYG
RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca	516 516 566	451 W DMNEPSNE 501 STHYNLHNLY 551	461 IRGSEDGCPN 511 GLTEAIASHR GLTEAIASHR 561	471 NELENPPYVP 521 ALVKARGTRP ALVKARGTRP 571	481 GVVCGTLQAA 531 FVISRSTFAG 581	491 TICASSHOFL 541 HGRYAGHWTO HGRYAGHWTO 591
RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A	516 516 566 566 616 616	451 WIDMNEPSNF 501 ISTHYNLHNLY ISTHYNLHNLY 551 D YWSSWEQLA O YWSSWEQLA	461 IRGSEDGCPN 511 GLTEAIASHR GLTEAIASHR 561 SSVPEILOFN SSVPEILOFN	471 NELENPPYVP 521 ALVKARGTRP ALVKARGTRP 571 LLGVPLVGAD	481 GVVGTLGAA 531 FVISRSTFAG FVISRSTFAG 581 VCGFLGNTSE VCGFLGNTSE	491 TICASSHOFL 541 HGRYAGHWTG HGRYAGHWTG 591 ELCVRWTQLG ELCVRWTQLG
RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A	516 516 566 566 616 616	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA 0VWSSWEQLA 601	481 IROSEDICCPN 511 GLTEAIASHR 581 SSVPEILOFN 611	471 NELENPPYVP 521 ALVKARGTRP 571 LLGVPLVGAD 621	481 G V V G T L Q A A G V V G T L Q A A S31 F V I S R S T F A G F V I S R S T F A G 581 V C G F L O N T S E V C G F L O N T S E 631	491 TICASSHQFL 541 HORVAGHWTO 591 ELCVRWTQLG 641
RMSD: ca Alpha Glucosidase.pdb, chain A Strav, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A	516 516 556 556 616 616	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 VWSSWEQLA 001 AFYPFMRNHN	481 IROSEDGCPN 511 GLTEAIASHR GLTEAIASHR 501 SSVPEILOFN SSVPEILOFN 611 SLLSLPQEPY	471 NELENPPYVP S21 ALVKARGTRP 571 LLGVPLVGAD LLGVPLVGAD 621 SFSEPAQQAM	481 GVVGGTLQAA GVVGGTLQAA S31 FVISRSTFAG 581 VCGFLONTSE VCGFLONTSE 631 RKALTLRYAL	491 TICASSHOFL 541 HORYAGHWIG HORYAGHWIG 591 ELCVRWIGLG ELCVRWIGLG 641 LPHLYILFHQ
RMSD: ca Alpha Gluccosidase.pdb, chain A Srzw, chain A Alpha Gluccosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Gluccosidase.pdb, chain A Sizw, chain A RMSD ca Alpha Gluccosidase.pdb, chain A Sizw, chain A	516 516 556 616 616 656	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 VWSSWEQLA 001 AFYPFMRNHN AFYPFMRNHN	481 IROSEDGCPN 511 GLTEAIASHR GLTEAIASHR 501 SSVPEILOFN SSVPEILOFN SLLSLPQEPY SLLSLPQEPY	471 NELENPPYVP NELENPPYVP 521 ALVKARGTRP 571 LLGVPLVGAD LGVPLVGAD 621 SFSEPAGGAW SFSEPAGGAW	481 GVVGGTLQAA GVVGGTLQAA S31 FVISRSTFAG 581 VCGFLONTSE VCGFLONTSE 631 RKALTLRYAL 844	491 TICASSHOFL 541 HORYAGHWIG 591 ELCVRWIGLG 641 LPHLYILFHQ PHLYILFHQ
RMSD: ca Alpha Gluccoidase.pdb, chain A Skrw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Skrw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Skrw, chain A RMSD: ca RMSD: ca RMSD: ca	516 516 556 556 616 616 656	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA DVWSSWEQLA 001 AFYPFMRNHN AFYPFMRNHN 651	481 IROSEDGCPN 511 GLTEAIASHR GLTEAIASHR 581 SSVPEILOFN SSVPEILOFN 611 SLLSLPOEPY 681	471 NELENPPYVP S21 ALVKARGTRP ALVKARGTRP 571 LLOVPLVGAD 621 SFSEPAQQAW 6FSEPAQQAW 671	491 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RKALTLRYAL 681	491 TICASSHOFL 541 HCRYAGHWTG 591 ELCVRWTQLG 641 LPHLYTLFHQ 691
RMSD: ca Alpha Gluccoidase.pdb, chain A Srzw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Sizw, chain A	516 516 556 556 616 616 616 606 716 716	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA DVWSSWEQLA 601 AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN 651 CANVAGETVAR	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 561 S S V P E I L O F N S S V P E I L O F N S S V P E I L O F N S S V P E I L O F N S L L S L P Q E P Y 661 P L F L E F P K D S	471 NELENPPYVP S21 ALVKARGTRP ALVKARGTRP 571 LLGVPLVGAD 621 SFSEPAQQAW 5FSEPAQQAW 671 STWTVDHQLL	491 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RKALTLRYAL 681 WGEALLITPV	491 TICASSHOFL 541 HORYAGHWTO 591 ELCVRWTOLO 641 LPHLYTLFHQ 691 LCACKAEVTO CACKAEVTO
RMSD: ca Alpha Gluccosidase.pdb, chain A Skrw, chain A RMSD: ca Alpha Gluccosidase.pdb, chain A Skrw, chain A RMSD: ca Alpha Gluccosidase.pdb, chain A Skrw, chain A RMSD: ca Alpha Gluccosidase.pdb, chain A Skrw, chain A	516 516 556 616 616 656 716 716	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA DVWSSWEQLA 0VWSSWEQLA 601 AFYPFMRNHN AFYPFMRNHN 651 AHVAGETVAR 701	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 561 S S V P E I L O F N S V P E I L O F N S V P E I L O F N S L L S L P O E P Y 661 P L F L E F P K D S 711	471 NELENPPYVP S21 ALVKARGTRP ALVKARGTRP 571 LLGVPLVGAD 621 SFSEPAQQAW 671 SFSEPAQQAW 671 STWTVDHQLL 57V1	491 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RKALTLRYAL 681 WGEALLITPV 731	491 TICASSHOFL TICASSHOFL 541 HCRYAGHWTG 591 ELCVRWTQLG 641 CPHLYTLFHQ 691 LCACKAEVTG CACKAEVTG CACKAEVTG CACKAEVTG CACKAEVTG 741
RMSD: ca Alpha Gluccoidase.pdb, chain A Skrw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Skrw, chain A	516 516 506 616 616 606 716 716 716	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA DVWSSWEQLA 601 A FYPFMRNHN A FYPFMRNHN 651 A HVAGETVAR 701 IVFPLGTWYDL	481 I ROSEDGCPN IROSEDGCPN 511 GLTEAIASHR 581 SSVPEILOFN SSVPEILOFN 611 SLLSLPQEPY 681 PLFLEFPKDS 711 GTVPIEALOS	471 NELENPPYVP S21 ALVKARGTRP ALVKARGTRP 571 LLGVPLVGAD 621 SFSEPAQQAW 671 SFSEPAQQAW 671 TUVDHQLL 721 LPPPPAA	491 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RKALTLRYAL 681 WGEALLITPY WGEALLITPY 731	491 TICASSHOFL TICASSHOFL 541 BORYAGHWTG 591 ELCVRWTQLG ELCVRWTQLG 641 LPHLYTLFHQ 691 LCACKAEVTG COACKAEVTG COACKAEVTG COACKAEVTG COACKAEVTG COACKAEVTG
RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glucosidase.pdb, chain A Sizw, chain A	516 516 556 616 616 606 606 716 716 706	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DWWSSWEQLA 601 AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN 651 ANVAGETVAR 701 IVFPLGTWYDL 774	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 581 S S V P E I L G F N S S V P E I L G F N S V P E I L G F N S L S L P Q E P Y 681 P L F L E F P K D S P L F L E F P K D S 711 G T V P I E A L G S G T V P I E A L G S	471 NELENPPYVP S21 ALVKARGTRP ALVKARGTRP 571 LLGVPLVGAD 621 SFSEPAQQAW 671 SFSEPAQQAW 671 TI LLGVPLVGAD 621 SFSEPAQQAW 671 COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN COMPAN CO	491 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RKALTLRYAL 681 WGEALLITPY 731 FR	491 TICASSHOFL 541 HORYAGHWTG 591 ELCVRWTQLG ELCVRWTQLG 641 LDPHLYTLFHQ 661 LCACKAEVTG CAACKAEVTG CAACKAEVTG 741 EPAIHSEQQW EPAIHSEQQW
RMSD: ca Alpha Glaccoidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Glaccoidase.pdb, chain A Sizw, chain A	516 556 555 616 616 656 656 716 716 756	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DWSSWEQLA 0WSSWEQLA 601 IAFYPFMRNHN 651 IAFYPFMRNHN 651 IAFYPFMRNHN AFYPFMRNHN 701 IYFPLQTWYDL 751	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 581 S V P E I L G F N S V P E I	471 NELENPPYVP 521 ALVKARGTRP 571 LLOVPLVGAD 621 SFSEPAOQAM 671 STWTVDHQLL STWTVDHQLL 571 LPPPPAA 	491 GVVGGTLQAA 6VVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RKALTLRYAL 681 WGEALLITPV 731 FRI	491 TICASSHOFL 541 FORVAGHWTG 591 ELCVRWTQLG ELCVRWTQLG 641 LPHLYTLFHO 691 LOAGKAEVTG COAGKAEVTG COAGKAEVTG COAGKAEVTG 741 EPAIHSEGOW 791
RMSD ca Alpha Gluccoidase.pdb, chain A Sizw, chain A RMSD ca Alpha Gluccoidase.pdb, chain A Sizw, chain A	5116 5116 5506 6116 6116 6016 6016 6016	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DWWSSWEQLA 0WWSSWEQLA 601 A FYPFMRNHN 651 A HVAGETVAR A HVAGETVAR 701 VFPLGTWYDL 751 VTLPAPLDTI	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 581 S S V P E I L G F N S S V P E I L G F N S V P	471 NELENPPYVP S21 ALVKARGTRP 571 LLGVPLVGAD LGVPLVGAD 621 SFSEPAGGAM 671 STWTVDHGLL STWTVDHGLL STWTVDHGLL 721 LPPPPAA 	481 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RXALTLRYAL 681 WGEALLITPV 731 FSFDOPPAAPR 781 ESFROOPMALA	491 TICASSHOFL 541 FORVAGHWTG 591 ELCVRWTQLG ELCVRWTQLG 641 LDALVRWTQLG 641 LDALVRWTQLG 691 LDACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG ICACKAEVTG
RMSD ca Alpha Glacosidase.pdb, chain A Sizw, chain A RMSD ca Alpha Glacosidase.pdb, chain A Sizw, chain A	516 506 506 616 606 716 716 706 706 805 805	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DWWSSWEQLA 601 AFYPFMRNHN AFYPFMRNHN 651 IAHVAGETVAR AHVAGETVAR 701 VFFLGTWYDL 751 VTLPAPLDTI 801	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 581 S S V P E I L G F N S V P E	471 NELENPPYVP NELENPPYVP 521 ALVKARGTRP 571 LLOVPLVGAD 621 SFSEPA00AM 671 SFSEPA00AM 671 STWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5TWTVDH0LL 5THTTE 821	491 GVVGGTLQAA GVVGGTLQAA 531 FVISRSTFAG 581 VCGFLGNTSE 631 RXALTLRYAL 681 WGEALLITPV 731 FRIESROGPMALA 683	491 TICASSHOFL FICASSHOFL 541 FORVAGHWTG 591 ELCVRWTQLG ELCVRWTQLG 641 LDACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG CAACKAEVTG
RMSD: ca Alpha Gluccoidase.pdb, chain A Sizw, chain A RMSD: ca Alpha Gluccoidase.pdb, chain A Sizw, chain A	516 556 556 616 616 616 656 716 716 716 756 756 805 805	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA 601 IAFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN 751 VTPLQTWYDL 751 VTLPAPLDTI VTLPAPLDTI 601 IGELFWDDGES	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 561 S S V P E I L O F N 551 S L L S L P O E P Y 611 S L L S L P O E P Y 615 P L F L E F P K D S P L F L E F P K D S 711 O T V P I E A L G S 0 T V P I E A L G S 715 N V H L R A G Y I I N V H L R A G Y I I N V H L R A G Y I I 811 L E V L E R O A Y T	471 NELENPPYVP S21 ALVKARGTRP S41 S52 S71 LLGVPLVGAD G21 SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA00AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEPA0AM SFSEP	481 GVVGGTLQAA GVVGGTLQAA S31 FVISRSTFAG 581 VCGFLQNTSE VCGFLQNTSE VCGFLQNTSE 781 RKALTLRYAL 681 WGEALLITPV 731 EEROOPMALA 851 IVNELVRVTS	491 TICASSHOFL 541 BORVAGHWTO FORVAGHWTO 591 ELCVRWTOLG ELCVRWTOLG 641 LPHLYTLFHO 691 LCAACKAEVTO CAACKAEVTO 741 EPAIHSEOOW PAIHSEOOW 791 VALTKOCEAR 841 ECAOLOLOKY
RMSD ca Alpha Gluccoidase.pdb, chain A Sizw, chain A RMSD ca Alpha Gluccoidase.pdb, chain A Sizw, chain A	5116 516 506 616 616 7116 716 716 706 805 805 855	451 WIDMNEPSNF 501 ISTHYNLHNLY 551 DVWSSWEQLA 601 IAFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN AFYPFMRNHN 751 VTPLQTWYDL 751 VTLPAPLDTI VTLPAPLDTI 751 VTLPAPLDTI 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001 1001	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G L T E A I A S H R 561 S S V P E I L O F N 581 S L L S L P O E P Y 661 P L F L E F P K D S P L F L E F P K D S 711 O T V P I E A L G S 0 T V P I E A L G S 715 N V H L R A G Y I I N V H L R A G Y I I N V H L R A G Y I I N V H L R A G Y I I S I L S L E P A G Y 761 N V H L R A G Y I I N V H L R A G Y I I S I L S L E P A G Y 761 N V H L R A G Y I I S I L S L E P A G Y 761 N V H L R A G Y I I S I L S L E P A G Y 761 N V H L R A G Y I I S I L S L E P A G Y 761 S I L S L C A G Y S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S L P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C A Y I S I L S I P C	471 NELENPPYVP S21 ALVKARGTRP S21 LGVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVGAD COVPLVCAD COVPLVGAD COVPLVCAD COVPL	481 GVVGGTLQAA GVVGGTLQAA S31 FVISRSTFAG 581 VCGFLQNTSE VCGFLQNTSE VCGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE CGFLQNTSE C	491 TICASSHOFL S41 HORVAGHWTG 591 ELCVRWTQLG ELCVRWTQLG ELCVRWTQLG 641 LPHLYTLFHO 691 LCAACKAEVTG 741 EPAIHSEOQW PAIHSEOQW 791 VALTKOCEAR 841 ECACLQLQKV ECACLQLQKV ES4
RMSD ca Alpha Glaccoidase.pdb, chain A Sizw, chain A RMSD ca	516 506 506 616 606 716 706 706 706 805 805 805	451 WIDMNEPSNF 501 ISTHYNLHNLY ISTHYNLHNLY 551 DVWSSWEQLA 601 AFYPFMRNHN AFYPFMRNHN 651 INVAGETVAR AHVAGETVAR AHVAGETVAR 107 751 VTLPAPLDTI VTLPAPLDTI 001 051 INTLPAPLDTI 001 051 ELFWDDGES 051	481 I R G S E D G C P N I R G S E D G C P N 511 G L T E A I A S H R G T E A I A S H R 531 S S V P E I L O F N 531 S S V P E I L O F N 531 S L L S L P Q E P Y 641 S L L S L P Q E P Y 641 S L L S L P Q E P Y 651 P L F L E F P K D S P L F L E F P K D S 711 O T V P I E A L G S 0 T V P I E A L G S 0 T V P I E A L G S 111 O T V P I E A L G S 111 O T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A L G S 111 0 T V P I E A	471 NELENPPYVP S21 ALVKARGTRP S21 LUKARGTRP 571 LUCVPLVCAD 621 SFSEPACQAM SFSEPACQAM SFSEPACQAM 671 STWTVDHQLL STWTVDHQLL 721 LPPPPAA 	481 GVVGGTLQAA GVVGGTLQAA S31 FVISRSTFAG 581 VCGFLONTSE VCGFLONTSE 483 RKALTLRYAL 681 RKALTLRYAL 681 FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPPAA FR SLPPPPPAA FR SLPPPPPPAA FR SLPPPPPAA FR SLPPPPPAA FR SLPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP	491 TICASSHQFL TICASSHQFL 541 HCRYAGHWTC 591 ECCVRWTQLC 641 LPHLYTLFHQ 691 LCACKAEVTC CACKAEVTC 741 EPALHSECOW 741 VALTXCCEAR VALTXCCEAR 841 ECACLQCXY 801

Figure 2. Alignment of target protein with the template.

3.2. Homology Modeling

The homology model of the target protein, α -glucosidase, was accomplished with MODELLER 9.20. The 3D structure of the protein was modeled for further docking studies. The 3D modeled structure of the protein is shown in Figure 3.



Figure 3. 3D modeled structure of α -glucosidase.

3.3. Validation of the Modeled Structure

The modeled structure validated by RAMPAGE, showing stereo-chemical verification, and the verified 3D structure by ERRAT, are shown in Figure 4. For protein structure verification, a Ramachandran plot was drawn with MOE, as shown in Figure 5.



Figure 4. Showing the 95% of amino acids in ideal range and are below rejection level.



Figure 5. Ramachandran plot and position of amino acids in α-glucosidase.

3.4. The Ramachandran Plot

The plot shows:

- (i) Number of residues in the favored region (~98.0% expected): 898 (94.32%)
- (ii) Number of residues in the allowed region ($\sim 2.0\%$ expected): 49 (5.1%)
- (iii) Number of residues in the outlier region: 5 (0.52%).

3.5. Active Site Prediction

After sequence alignment, formation of the 3D structure and the verification of its active site, for ligands in the target protein, was predicted with the MOE software. The active site of the target protein was comprised of amino acids GLU174, THR175, AR178, GLU196, THR197, PRO198, ARG199, VAL200, HIS201, SER202, ARG203, ALA204, PRO205, GLN352, LEU355, ASP356, VAL357, VAL358, GLY359, TYR360, ARG608, VAL718, ALA719.

3.6. Preparation of Protein and Molecular Docking

Proteins were prepared for molecular docking by 3D protonation, energy minimization and prediction of active site for ligands, keeping the parameters at their defaults. Next, ligands were docked with the target protein (α -glucosidase) while using MOE software. The docking results suggested that Nummularine-R was the most potent of the tested compounds, with a docking score of -14.5691 followed by Vindoline with a docking score of -13.2250. In addition to these two compounds, Conophyline, Epiberberine, glutamic acid, and mahanimbilylacetate also showed favorable results. The docking results, along with ligand structure and their properties, are shown in Table 1.

Plant	Molecular Structures	Activity	Docking Score	Ref.
Ervatamia microphylla (leaves)	Conophyline 1	In vivo p.o. stimulate iPMSCs proliferation	-12.6274	[1]
Murraya koenigii (leaves)	Bicyclomahanimbiline 2	In vivo p.o. Hypoglycemic Activity	-11.7634	[2]
Murraya koenigii (leaves)	Girinimbilylacetat 3	In vivo p.o. Hypoglycemic Activity	-9.5231	[2]
Murraya koenigii (leaves)	Girinimbine 4	In vivo p.o. Hypoglycemic Activity	-9.9589	[2]
Murraya koenigii (leaves)	Mahanimbilylacetate 5	In vivo p.o. Hypoglycemic Activity	-12.9971	[2]

Table 1. Ligand chemical structures, their properties, and docking scores.

Plant	Molecular Structures	Activity	Docking Score	Ref.
<i>Coptis chinensis</i> (Rhizome)	Jatrorrhizine 6	In vitro anti-diabetic	-9.3385	[3,4]
<i>Coptis chinensis</i> (Rhizome)	Magnoflorine 7	In vitro anti-diabetic	-11.2586	[3,4]
<i>Coptis chinensis</i> (Rhizome)	Palmatine 8	In vitro Anti-diabetic	-10.0536	[3,4]
Catharanthus roseus (Leaves)	Vindolicine 9	In vitro Anti-diabetic	-9.2272	[5]
Catharanthus roseus (Leaves)	Vindoline 10	In vitro Anti-diabetic	-13.2250	[5]
Catharanthus roseus (Leaves)		In vitro Anti-diabetic	-5.5275	[5]

Vindolinine 11

Table	1.	Cont
Table	т.	Com.

Plant	Molecular Structures	Activity	Docking Score	Ref.
<i>Ziziphus oxyphylla</i> (Whole plant)	Hemsine-A 12	In vitro Control the postprandial hyperglycemia	-10.4509	[6]
Ziziphus oxyphylla (Whole plant)	Nummularin-C 13	In vitro Anti-diabetic Control the postprandial hyperglycemia	-10.3726	[6]
Ziziphus oxyphylla (Whole plant)	Nummularine-R 14	In vitro Anti-diabetic Control the postprandial hyperglycemia	-14.5691	[6]
Berberis lyceum (Root)	Berberine 15	In vitro Anti-diabetic Hypoglycemic Activity	-10.5667	[7]
Coptis japonica (Root)	Columbamine 16	In vitro Anti-diabetic Aldose Reductase Inhibitory Activity	-7.4609	[3]
Coptis chinensis (Rhizome)	Coptisine 17	Anti-diabetic	-8.9123	[3,4]

Table 1. Cont.

Plant	Molecular Structures	Activity	Docking Score	Ref.
Coptis chinensis (Rhizome)	Epiberberine 18	In vitro Anti-diabetic	-12.9822	[3,4]
<i>Coptis japonica</i> (Root)	Glutamic acid 19	In vitro Anti-diabetic Aldose Reductase Inhibitory Activity	-12.6023	[3]
Coptis chinensis (Rhizome)	Groenlandicine 20	In vitro Anti-diabetic	-7.0817	[3,4]
Coptis chinensis (Rhizome)	Jateorrhizine 21	In vitro Anti-diabetic	-11.4544	[3,4]
Coptis japonica (Root)	Dehydrocheilanthifoline 22	In vitro Anti-diabetic Aldose Reductase Inhibitory Activity	-10.8606	[3]
<i>Tecoma stans</i> (Leaves)	β-hydroxyskitanthine 23	In Vivo and In Vitro Potent stimulating effect on the basal glucose uptake rate	-10.2216	[8]

Table 1. Cont.

Plant	Molecular Structures	Activity	Docking Score	Ref.
Tecoma stans (Leaves)	Boschnlakine 24	In Vivo and In Vitro Potent stimulating effect on the basal glucose uptake rate	-7.6929	[8]
Tecoma stan (Leaves)	Tecomine 25	In Vivo and In Vitro Potent stimulating effect on the basal glucose uptake rate	-9.1085	[8]
Tecoma stans (Leaves)	Tecostanine 26	In Vivo and In Vitro Potent stimulating effect on the basal glucose uptake rate	-9.9845	[8]
Nigella glandulifera. (Seed)	Nigelladines A 2 7	In Vitro PTP1B inhibitory activity	-	[9]
Nigella glandulifera. (Seed)	Nigelladines B 28	In Vitro PTP1B inhibitory activity	-9.7263	[9]
Nigella glandulifera. (Seed)	Nigelladines C 29	In Vivo and In Vitro PTP1B inhibitory activity	-9.9462	[9]

Table 1. Cont.

Plant	Molecular Structures	Activity	Docking Score	Ref.
Nigella glandulifera. (Seed)	Nigellaquinomine 30	In Vitro PTP1B inhibitory activity	-10.7638	[9]
Nigella glandulifera. (Seed)	Pyrroloquinoline 31	In Vitro PTP1B inhibitory activity	-9.4846	[9]
<i>Brassica oleracea</i> var. capitate (Seed)	2,3-Dicyano-5,6-diphenylpyrazine 32	Antidiabetic activity	-9.6067	[10]
34	Miglitol		-15.4423	
35	Acarbose		-14.7983	

Table 1. Cont.

4. Discussion

Molecular docking is frequently used to predict the binding orientation of small molecules and drug candidates to their protein targets in order to predict their affinity and activity [28,29]. In this study, we modeled various alkaloids isolated from different plants and known for their inhibition of α -glucosidase through molecular docking.

Glucose control is an effective and long-lasting treatment for type II diabetes mellitus, minimizing both cardio-vascular and nervous system symptoms associated with the disease [30,31]. α -glucosidase

petic patients to decrease postprandial hyperglycen

inhibitors are usually recommended for diabetic patients to decrease postprandial hyperglycemia caused by the breakdown of starch molecules in the small intestine [32]. The use of plants or plant-based substances may be a suitable source of α -glucosidase inhibitors because of their low price and comparatively greater safety, with a low frequency of serious gastrointestinal side effects [33].

The docked alkaloids also exhibit inhibitory potential against other hydrolase enzymes in the same class. Previous reports [21] shows that alkaloids such as berberine and palmatine inhibit aldose reductase activity at lower concentrations, losing their inhibitory potential at higher concentrations. On the other hand, coptisine, epiberberine, and groenlandicine showed reasonable inhibitory potential. Nigelladines A–C, pyrroloquinoline and nigellaquinomine have shown strong protein tyrosine phosphatase inhibitory activity [25].

Among the 10 differencing docking alkaloids, nummularine-R was found to be the most potent of the tested compounds with a docking score of -14.5691, followed by Vindoline with a docking score of -13.2250. Both these compounds have good inhibitory activity and their docking score is in the region of certain standard ligands, such as miglitol (-15.4423) and acarbose (-14.7983). Furthermore, both these ligands exhibited a good interaction with α -glucosidase. The most potent ligand, nummularine-R, formed four hydrogen interactions with the Gln121, Met122, Arg331, and Gly546 active amino acid residues. Gln121 was observed to make a polar hydrogen bond, with the oxygen atom double bonding with the piperidine moiety of the ligand. Arg331 formed polar hydrogen bonds with the Nitrogen atom of the pentene ring of the ligand. Met122 showed acidic hydrogen interactions, whereas Gly546 showed basic hydrogen interactions with the oxygen atom double bonding with the piperidine moiety of the same ligand. These interactions are shown in Figure 6A. Ala93, Ala97, Gln121, and Trp126 formed three Hydrogen and one arene-arene interaction with the ligand. Ala93 showed greasy hydrogen interaction with the nitrogen of the benzene ring, with a bond length of 3.07 A, while Gln121 showed greasy hydrogen interaction with the hydrogen of the benzene ring, with a bond length of 3.01 Å. Ala97 demonstrated a basic hydrogen bond with an oxygen atom double bonding with the piperidine moiety of the ligand with a bond length of 3.07 Å. Trp126 exhibited an arene-arene bond with a bond length of 3.89 Å with the benzene ring of the inhibitor. All these interactions are shown in Figure 6B.



Figure 6. 2D images of the docked conformations of the ligands and standard with the active residues (**A**) 2D image of nummularine-R (**B**) 2D image of Vindoline (**C**) 2D image of miglitol, and (**D**) 2D image of acarbose.

The reference compound Miglitol revealed four hydrogen bonds with Met122, Arg275 and Arg331 of the target protein active site residue. Met122 formed two acidic hydrogen bonds with the hydrogen and oxygen of the same phenol moiety, while Arg331 bound via polar hydrogen interaction with the oxygen of the benzene ring of the phenol moiety of the ligand. Arg275 formed a polar hydrogen bond with the oxygen atom, double bonding with the piperidine moiety of the same compound. All these bonds are shown in Figure 6C. Another reference compound, Acarbose, showed seven hydrogens, Ala93, Ile98, Gln121, Met122, Arg275, Pro545 and one arene-cation interaction with Trp126 of the target protein. Ala93 and Met122 formed greasy and acidic hydrogen bonds with the nitrogen of the benzene ring. Met122 also formed acidic hydrogen with the carbon backbone of the benzene ring. Gln121 formed a greasy hydrogen interaction with the carbon of the benzene backbone. Arg275 exhibited a polar hydrogen bond with the OH group of the phenol moiety, similarly Pro545 possessed greasy hydrogen and Ile98 formed basic hydrogen interactions with the target protein. Trp126 exhibited an arene-cation bound with the carbon backbone of the ligand. All these bonds are shown in Figure 6D. The 3D interaction of the most potent ligands (nummularine-R and Vindoline) and standard (Acarbose and Miglitol) with target protein are shown in Figures 7–10, respectively. Similarly, these docking results were consistent and in full agreement with the in vitro anti-diabetic activity previously reported [18,19]. In addition to nummularine-R and Vindoline, Conophyline, Epiberberine, Glutamic acid and Mahanimbilylacetate also showed good interactions with the target protein, with docking scores of -12.6274, -12.9822, -12.6023, -12.9971, -12.7703, respectively.



Figure 7. 3D interaction of most active compound 14 (Nummularine-R).



Figure 8. Interaction of compound **10** (Vindoline) with Ligand target protein. Ala93, Ala97, Gln121, and Trp126 form three Hydrogen and one arene-arene interaction with the ligand.



Figure 9. 2D interactions of standard (acarbose). Acarbose showed seven hydrogen, Ala93, Ile98, Gln121, Met122, Arg275, Pro545, and one arene-cation interaction with Trp126 of the target protein.



Figure 10. Interaction of reference compound (Miglitol). Miglitol shows four hydrogen bonds with Met122, Arg275, and Arg331 of the target protein active site residue.

Nummularine-R, formed four hydrogen interactions, with the Gln121, Met122, Arg331, and Gly546 active amino acid residues.

5. Conclusions

The molecular docking of 32 alkaloids isolated from various plants, along with the standard compounds acarbose and miglitol, were docked to α -glucosidase by using MOE-Dock applied in MOE software to predict the binding modes of these drug-like compounds. The results showed that nummularine-R and Vindoline possessed striking interactions with active site residues of the target protein, α -glucosidase, and were analogous to reference ligands. Taken together, the current study provides a computational background for several α -glucosidase inhibitors. Future studies should more carefully examine the clinical efficacy of these compounds, thus facilitating the development of novel resources for the treatment of diabetes mellitus.

Author Contributions: N.R., I.M. and G.-E.-N. carried out initial experimental work and initiated draft. H.K., M.D. and M.A. checked the initial draft, finalized the manuscript and supervised the overall project, while finalized the draft. Writing—review & editing, R.F.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Bharatham, K.; Bharatham, N.; Hun, K.; Woo, K. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of a glucosidase inhibitors. *J. Mol. Graph. Model.* 2008, 26, 1202–1212. [CrossRef] [PubMed]
- 2. Alongi, M.; Verardo, G.; Gorassini, A.; Anese, M. Effect of pasteurization on in vitro α-glucosidase inhibitory activity of apple juice. *LWT* **2018**, *98*, 366–371. [CrossRef]
- 3. Krasikov, V.V.; Karelov, D.V.; Firsov, L.M. α-glucosidases. *Biochemistry (Moscow)* **2001**, *66*, 267–281. [CrossRef] [PubMed]
- Bruni, C.B.; Sica, V.; Auricchio, F.; Covelli, I. Further kinetic and structural characterization of the lysosomal α-D-glucoside glucohydrolase from cattle liver. *Biochim. Biophys. Acta* (*BBA*)-*Enzymol.* **1970**, 212, 470–477. [CrossRef]
- 5. Flanagan, B.P.R.; Forstner, G.G. Purification of Rat Intestinal Maltase/Glucoamylase and its Anomalous Dissociation either by Heat or by Low pH. *Biochem. J.* **1978**, *173*, 553–563. [CrossRef] [PubMed]
- 6. Arinaminpathy, Y.; Khurana, E.; Engelman, D.M.; Gerstein, M.B. Computational analysis of membrane proteins: The largest class of drug targets. *Drug Discov. Today* **2009**, *14*, 1130–1135. [CrossRef] [PubMed]
- 7. Biochem, E.J.; Universitet, K. Amp hip hilic Pig Intestinal Microvillus Malt ase/Glucoam ylase Structure and Specificity. *Eur. J. Biochem.* **1982**, 126, 559–568.
- 8. Sun, Z.; Duke, H.; Henson, C.A. The Role of Pea Chloroplast a-Glucosidase in Transitory Starch Degradation. *Plant Physiol.* **1995**, *108*, 211–217. [CrossRef] [PubMed]
- 9. Sun, Z.; Henson, C.A.; Crops, C. Degradation of Native Starch Granules by Barley. *Plant Physiol.* **1990**, *94*, 320–327. [CrossRef]
- 10. Ishii, T. Feruloyl oligosaccharides from cell walls of suspension-cultured spinach cells and sugar beet pulp. *Plant Cell Physiol.* **1994**, *35*, 701–704. [CrossRef] [PubMed]
- 11. Pervaiz, A.; Khan, R.; Anwar, F.; Mushtaq, G.; Kamal, M.A. Alkaloids: An emerging antibacterial modality against methicillin resistant Staphylococcus aureus. *Curr. Pharm. Des.* **2016**, *22*, 4420–4429. [CrossRef] [PubMed]
- 12. Ahmad, S.; Khan, H.; Siddiqui, Z.; Khan, M.Y.; Rehman, S.; Shahab, U.; Godovikova, T.; Silnikov, V. April. AGEs, RAGEs and s-RAGE; friend or foe for cancer. *Semin. Cancer Biol.* **2018**, *49*, 44–55. [CrossRef] [PubMed]
- 13. Perviz, S.; Khan, H.; Pervaiz, A. Plant Alkaloids as an Emerging Therapeutic Alternative for the Treatment of Depression. *Front. Pharmacol.* **2016**, *7*, 28. [CrossRef] [PubMed]
- 14. Khan, H.; Mubarak, M.S.; Pervaiz, A. Plant Alkaloids as Antiplatelet Agent: Drugs of the Future in the Light of Recent Developments. *Front. Pharmacol.* **2016**, *7*, 292. [CrossRef]
- 15. Fujii, M.; Takei, I.; Umezawa, K. Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats. *Biomed Pharm.* **2009**, *63*, 710–716. [CrossRef]
- Sangeetha, M.K.; Priya, C.D.M.; Vasanthi, H.R. Phytomedicine Anti-diabetic property of Tinospora cordifolia and its active compound is mediated through the expression of Glut-4 in L6 myotubes. *Eur. J. Integr. Med.* 2013, 20, 246–248. [CrossRef]
- 17. Patel, M.B.; Mishra, S. Phytomedicine Hypoglycemic activity of alkaloidal fraction of Tinospora cordifolia. *Eur. J. Integr. Med.* **2011**, *18*, 1045–1052. [CrossRef]
- Choudhary, M.I.; Adhikari, A.; Rasheed, S.; Marasini, B.P.; Hussain, N.; Kaleem, W.A. Cyclopeptide alkaloids of Ziziphus oxyphylla Edgw as novel inhibitors of α-glucosidase enzyme and protein glycation. *Phytochem. Lett.* **2011**, *4*, 404–406. [CrossRef]
- Don, C.L.G. Antidiabetic and Antioxidant Properties of Alkaloids from *Catharanthus roseus* (L.) G. Don. *Molecules* 2013, 18, 9770–9784. [CrossRef]

- Al, M.G.E.T.; Gulfraz, M.; Mehmood, S.; Ahmad, A.; Fatima, N.; Praveen, Z.; Williamson, E.M. Comparison of the Antidiabetic Activity of Berberis lyceum Root Extract and Berberine in Alloxan-induced Diabetic Rats. *Phytother. Res.* 2008, 22, 1208–1212. [CrossRef]
- 21. Jung, H.A.; Yoon, N.Y.; Bae, H.J.; Min, B.-S.; Choi, J.S. Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. *Arch. Pharm. Res.* **2008**, *31*, 1405–1412. [CrossRef] [PubMed]
- 22. Jung, M.; Park, M.; Lee, H.C.; Kang, Y.; Kang, E.S.; Kim, K. Antidiabetic Agents from Medicinal Plants. *Curr. Med. Chem.* **2006**, *13*, 1203–1218. [CrossRef] [PubMed]
- 23. Ali, S.; Igoli, J.; Clements, C.; Semaan, D.; Alamzeb, M.; Mamoon-Ur-Rashid Shah, S.Q.; Ferro, V.A.; Gray, A.I.; Khan, M.R. Antidiabetic and antimicrobial activities of fractions and compounds isolated from Berberis brevissima Jafri and Berberis parkeriana Schneid. *Bangladesh J. Pharm.* **2013**, *8*, 336–342. [CrossRef]
- Adebajo, A.C.; Ayoola, O.F.; Iwalewa, E.O.; Akindahunsi, A.A.; Omisore, N.O.A.; Adewunmi, C.O.; Adenowo, T.K. Anti-trichomonal, biochemical and toxicological activities of methanolic extract and some carbazole alkaloids isolated from the leaves of Murraya koenigii growing in Nigeria. *Phytomedicine* 2006, 13, 246–254. [CrossRef] [PubMed]
- 25. Chen, Q.B.; Xin, X.L.; Yang, Y.; Lee, S.S.; Aisa, H.A. Highly conjugated norditerpenoid and pyrroloquinoline alkaloids with potent ptp1b inhibitory activity from nigella glandulifera. *J. Nat. Prod.* **2014**, *77*, 807–812. [CrossRef]
- Costantino, L.; Raimondi, L.; Pirisino, R.; Brunetti, T.; Pessotto, P.; Giannessi, F.; Lins, A.P.; Barlocco, D.; Antolini, L.; El-Abady, S.A. Isolation and pharmacological activities of the Tecoma stans alkaloids. *Farmaco* 2003, 58, 781–785. [CrossRef]
- 27. Goodford, P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. *J. Med. Chem.* **1985**, *28*, 849–857. [CrossRef]
- 28. Seeliger, D.; Groot, B.L.; De Pymol, V. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. *J. Comput. Aided Mol. Des.* **2010**, *24*, 417–422. [CrossRef]
- 29. Rauf, M.A.; Zubair, S.; Azhar, A. Ligand docking and binding site analysis with pymol and autodock/vina. *Int. J. Basic Appl. Sci.* **2015**, *4*, 168–177. [CrossRef]
- Blonde, L. Benefits and Risks for Intensive Glycemic Control in Patients With Diabetes Mellitus. *Am. J. Med. Sci.* 2012, 343, 17–20. [CrossRef]
- Zafar, M.; Khan, H.; Rauf, A.; Khan, A.; Lodhi, M.A. In Silico study of alkaloids as α-glucosidase inhibitors: Hope for the Discovery of effective lead compounds. *Front. Endocrinol.* 2016, 7, 153. [CrossRef] [PubMed]
- Bolen, S.; Feldman, L.; Vassy, J.; Wilson, L.; Yeh, H. Review Annals of Internal Medicine Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. *Ann. Intern. Med.* 2019, 147, 386–399. [CrossRef] [PubMed]
- 33. Benalla, W.; Bellahcen, S.; Bnouham, M. Antidiabetic Medicinal Plants as a Source of Alpha Glucosidase Inhibitors. *Curr. Diabetes Rev.* 2010, *6*, 247–254. [CrossRef] [PubMed]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).